ASCO 2017 | How can BCMA be used as a target for mutiple myeloma treatment?
Sagar Lonial
• 2 Jun 2017
Sagar Lonial, MD, FCAP, from the Winship Cancer Institute, Atlanta, GA, explores the question of what is the best way to use BCMA (B-cell maturation antigen) as a target for multiple myeloma treatment. He explains that they are hopeful that targeting BCMA will have a great impact on myeloma, just as CD38 has had. Previous studies have seen data on a BCMA drug conjugate. There also is emerging data on BCMA as a bispecific and there are now two or three groups who have published data on BCMA for CAR-T cells. However, Dr Lonial explains that although there is currently not enough data, he is hopeful that within the next few years, the best approach will be known.
